Loading, Please Wait...
MINNEAPOLIS, May 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 16th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 29, 2019, at the Depot Renaissance Minneapolis Hotel in Minneapolis, MN. Management will be available to participate in one-on-one meetings with investors and attendees can contact their Craig-Hallum representative to arrange a meeting.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company currently has an ongoing phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”
For more information, please visit www.diamedica.com.
Chief Financial Officer
Phone: (763) 496-5118
Vice President of Business Development
Phone: (617) 899-5941